Search hospitals > Illinois > Peoria

Illinois CancerCare-Peoria

Claim this profile
Peoria, Illinois 61615
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
688 reported clinical trials
9 medical researchers
Photo of Illinois CancerCare-Peoria in PeoriaPhoto of Illinois CancerCare-Peoria in PeoriaPhoto of Illinois CancerCare-Peoria in Peoria

Summary

Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 594 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.

Area of expertise

1Cancer
Global Leader
Illinois CancerCare-Peoria has run 187 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Illinois CancerCare-Peoria has run 111 trials for Breast Cancer. Some of their research focus areas include:
ER positive
Stage IV
HER2 negative

Top PIs

Clinical Trials running at Illinois CancerCare-Peoria

Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Gastric Cancer
Bladder Cancer
Esophageal Cancer
Squamous Cell Carcinoma
Esophageal Adenocarcinoma
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Illinois CancerCare-Peoria?
Illinois CancerCare-Peoria is a medical facility located in Peoria, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Illinois CancerCare-Peoria is involved with conducting 688 clinical trials across 594 conditions. There are 9 research doctors associated with this hospital, such as Bryan A. Faller, James L. Wade, Leonard Klein, and Nguyet A Le-Lindqwister, MD.
Where is Illinois CancerCare-Peoria located?
**Illinois CancerCare - Peoria Hospital** - **Address:** 8940 N Wood Sage Rd, Peoria, IL 61615 - **Hours:** - Monday to Thursday: 7:30 AM - 5:00 PM - Friday: 8:00 AM - 5:00 PM
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Peoria Financial Assistance:** - For financial assistance, contact OSF HealthCare Patient Financial Services at (800) 421-5700 or visit 1420 W. Pioneer Parkway, Peoria, IL 61615. - Assistance is available for those who qualify, including the uninsured and underinsured. Proof of income and state residency is required. - Pre-approval for financial assistance is available and typically processed within two weeks, valid for 12 months. **Insurance Inquiries:** - For insurance questions, contact Illinois CancerCare-Peoria at (309) 243-3000 or (866) 662-6564, or visit 8940 N Wood Sage Rd, Peoria, IL 61615. - They address inquiries related to treatment, research, and education in the fight against cancer and blood disorders.
What insurance does Illinois CancerCare-Peoria accept?
Illinois CancerCare-Peoria accepts a range of insurance plans, both commercial and government. Patients with HMO or PPO plans should verify if specific physicians are covered. It's also recommended to check if pre-certification is required with your insurance plan.
What awards or recognition has Illinois CancerCare-Peoria received?
Illinois CancerCare-Peoria, located in Peoria, Illinois, is renowned for its exceptional contribution to clinical research, being named one of the nation's top enrollers by the Alliance for Clinical Trials in Oncology in 2015. The hospital has also earned recognition from the Quality Oncology Practice Initiative (QOPI®) Certification Program, affirming its adherence to the highest standards of quality cancer care. Demonstrating its commitment to advancing cancer treatment, Illinois CancerCare-Peoria has successfully enrolled 201 patients into 30 different NCI-funded clinical trials across more than 15 cancer types.